
In this episode, Dr Aarti Bhatia and Dr Deborah Wong discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing considerations, and future precision oncology approaches for HPV-positive and HPV-negative patients with head and neck cancer. Presenters: Aarti Bhatia, MD, MPH Associate Professor of Medicine (Medical Oncology) Clinical Research Team Leader, Head and Neck Cancers Program Yale Cancer Center New Haven, Connecticut Deborah J. Wong, MD, PhD Director, Head and Neck Medical Oncology Program Associate Clinical Professor of Medicine Division of Hematology/Oncology University of California, Los Angeles (UCLA) Los Angeles, California Link to full program: https://bit.ly/49kViqg Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies

Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

Thrombotic Events and ET/PV: What You Should Know

Global Experts Discuss Current and Emerging Treatments for ET and PV
Free AI-powered recaps of Decera Clinical Education Oncology Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.